Anil Seetharam, MD
Gastroenterology · Scottsdale, AZNPI 1023229408
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,107 of the $111,304 with a category attached, or 76.5%. 37 manufacturers reported payments, led by Gilead at 31.3% of the total. 2025 is the largest year on record at $52,054, 2.5 times the $20,708 reported in 2019. Among gastroenterology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $345.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$35K
- Novo Nordisk$27K
- Madrigal Pharmaceuticals$18K
- Ipsen Biopharmaceuticals, Inc$13K
- GSK$10K
- W. L. Gore & Associates, Inc.$3K
- plus $6K from 31 others
What the payments were for
- Consulting fees$10,94310%
- Speaking & faculty fees$85,10776%
- Travel & lodging$6,8886%
- Food & beverage$8,2207%
- Education$190%
- Other$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 80 | $34,788 |
| Novo Nordisk | 13 | $27,244 |
| Madrigal Pharmaceuticals | 24 | $18,129 |
| Ipsen Biopharmaceuticals, Inc | 21 | $12,611 |
| GSK | 2 | $9,600 |
| W. L. Gore & Associates, Inc. | 2 | $3,265 |
| AstraZeneca | 1 | $1,343 |
| AbbVie(2 entities) | 20 | $457 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $439 |
| Sanofi | 14 | $433 |
| Johnson & Johnson | 12 | $389 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $325 |
| Phathom Pharmaceuticals, Inc. | 19 | $319 |
| QOL Medical, LLC | 10 | $295 |
| Regeneron Healthcare Solutions, Inc. | 10 | $279 |
| Lilly USA, LLC | 12 | $204 |
| Intercept Pharmaceuticals, Inc. | 10 | $160 |
| Pfizer | 2 | $139 |
| Pentax Of America, Inc. | 1 | $127 |
| Ardelyx, Inc. | 4 | $110 |
| Aimmune Therapeutics, Inc. | 3 | $79 |
| Celltrion USA Inc. | 4 | $78 |
| Bristol Myers Squibb | 3 | $75 |
| Shionogi Inc | 4 | $63 |
| Merck | 2 | $52 |
| Braintree Laboratories, Inc. | 3 | $47 |
| Organon | 1 | $32 |
| Capsovision, Inc. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Orphalan Inc | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Axonics, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Bayer | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$111,304 in reported general payments places this provider in the 95th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $377,466 |
| XifaxanRifaximin | 14 | $44,088 |
| LinzessLinaclotide | 34 | $25,819 |
| VemlidyTenofovir Alafenamide | 14 | $19,444 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 267 | $17,591 |
| Ursodiol | 43 | $6,928 |
| Budesonide DrBudesonide | 19 | $3,197 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 17 | $2,743 |
| Sucralfate | 27 | $2,277 |
| Pantoprazole Sodium | 117 | $1,599 |
| Azathioprine | 17 | $1,292 |
| CholestyramineCholestyramine (With Sugar) | 11 | $1,259 |
| Hydrocortisone | 25 | $850 |
| Omeprazole | 81 | $543 |
| Esomeprazole Magnesium | 16 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $389 | $377,46613 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $325 | $44,08814 claims |
| AbbVieLinzess | $457 | $25,81934 claims |
| GileadVemlidy | $34,788 | $19,44414 claims |
| Braintree Laboratories, Inc.Sutab | $47 | $2,74317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Scottsdale
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
- Woong KimScottsdale$138K
- Adam HarrisScottsdale$127K
- Amar ThosaniScottsdale$97K
- Manreet KaurScottsdale$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.